Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Maintenance Treatment (Trastuzumab and Pertuzumab) After Initial Chemotherapy in a Phase Ib/II Trial for Advanced HER2 Positive Breast Cancer
Phase 1/2 Terminated
2 enrolled 6 charts
Bevacizumab in Treating Patients With Metastatic Breast Cancer That Overexpresses HER-2/NEU
Phase 3 Terminated
96 enrolled 16 charts
Trastuzumab in Treating Patients With Locally Advanced or Metastatic Gallbladder Cancer or Bile Duct Cancer That Cannot Be Removed by Surgery
Phase 2 Terminated
4 enrolled 6 charts
Trastuzumab and Ixabepilone in Treating Women With HER2-Positive Metastatic Breast Cancer
Phase 2 Terminated
39 enrolled 8 charts
Akt Inhibitor MK2206, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With Locally Advanced or Metastatic HER2-Positive Breast , Gastric, or Gastroesophageal Cancer That Cannot Be Removed By Surgery
Phase 1 Terminated
60 enrolled
Trastuzumab in Treating Patients With Previously Treated, Locally Advanced, or Metastatic Cancer of the Urothelium
Phase 2 Terminated
40 enrolled
Combination Chemotherapy Plus Trastuzumab in Treating Patients With Advanced, Recurrent, or Metastatic Colorectal Cancer
Phase 2 Terminated
26 enrolled
Trastuzumab in Treating Patients With Metastatic or Recurrent Salivary Gland Cancer
Phase 2 Terminated
35 enrolled
Trastuzumab and Flavopiridol in Treating Patients With Metastatic Breast Cancer
Phase 1 Terminated
50 enrolled
Combination Chemotherapy, Surgery, and Radiation Therapy With or Without Dexrazoxane and Trastuzumab in Treating Women With Stage III or Stage IV Breast Cancer
Phase 3 Terminated
396 enrolled